Quick Takeaways
- ORBIS INVESTMENT MANAGEMENT LTD filed SCHEDULE 13G for CRISPR Therapeutics AG Common Stock (CRSP).
- Disclosed ownership: 5.5%.
- Date of event: 30 Sep 2025.
ORBIS INVESTMENT MANAGEMENT LTD - 30 Sep 2025 SCHEDULE 13G Report for CRISPR Therapeutics AG Common Stock (CRSP)
- Filing Manager
- ORBIS INVESTMENT MANAGEMENT LTD
- Reporting Manager
- ORBIS INVESTMENT MANAGEMENT LTD
- Security
- CRISPR Therapeutics AG Common Stock
- Symbol
- CRSP
- Shares outstanding
- 90,438,636 shares
- Disclosed Ownership
- 4,974,125 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 12:26:20 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIS INVESTMENT MANAGEMENT LTD disclosed 5.5% ownership in CRISPR Therapeutics AG Common Stock (CRSP) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 12:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ORBIS INVESTMENT MANAGEMENT LTD | 5.5% | 4,974,125 | 4,974,125 | 0 | Matthew Gaarder | Attorney-in-Fact | |
| Allan Gray Australia Pty Ltd | 0% | 7,960 | 7,960 | 0 | Matthew Gaarder | Attorney-in-Fact |